Observational studyAsia-Pacific journal of clinical oncology2026
Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer.
Observational study in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe underlying biology and genetic status of rectal cancer can guide treatment options. However, there is limited understanding of the impact of underlying mutational status of RAS/RAF on TNT response in metastatic rectal cancer. This study aims to determine treatment response to TNT in patients harboring RAS/RAF mutations.
methodsThis prospective multicenter observational study identified patients diagnosed with synchronous metastatic rectal cancer suitable to receive personalized TNT (pTNT) treated with curative intent between 2019 and 2024. Metastatic treatment response to pTNT was compared between patient groups based on RAS/RAF mutational status. Three-year disease free (DFS) and overall survival (OS) were compared.
resultsSeventy Stage IV rectal cancer patients were treated with curative intent and 49 had genetic testing available for inclusion. Among them, 27 (55.1%) patients had mutations (mRAS group) and 22 patients (44.9%) were wild-type (wtRAS group). mRAS patients were older than wtRAS patients (median 65.0 [60.0-71.0] vs. 55.5 years [39.0-69.25] respectively, p = 0.037). Synchronous metastases occurred more commonly in the liver than in the lungs (53.1% vs. 16.3%, p = 0.014). Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients (22.2% vs. 40.9%, p = 0.158) and disease progression was higher in patients harboring RAS mutations (37.0% vs. 22.7%, p = 0.280), but neither were significant. Differences in 3-year DFS and OS between the two groups did not reach significance.
conclusionRAS/RAF mutations may negatively impact metastatic tumor response rates in curative Stage IV rectal cancer patients treated with pTNT. Larger scale studies are needed to verify these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.